Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Women with BRCA1/BRCA2 pathogenic variants (PV) have a low initial breast cancer risk after ovarian cancer diagnosis, likely due to chemotherapy. However, risk increases significantly after 10 years, especially for BRCA1 carriers.
Area Of Science
- Oncology
- Genetics
- Cancer Epidemiology
Background
- Germline BRCA1/BRCA2 pathogenic variants (PV) are associated with elevated lifetime risks of breast and ovarian cancers.
- Limited data exists on breast cancer incidence following an ovarian cancer diagnosis in individuals with these variants.
Purpose Of The Study
- To assess the incidence and patterns of breast cancer in women with germline BRCA1/BRCA2 PV after an ovarian cancer diagnosis.
- To evaluate the impact of platinum-based chemotherapy on subsequent breast cancer risk.
Main Methods
- Retrospective review of breast cancer history in 895 women with BRCA1/BRCA2 PV heterozygotes (541 with BRCA1 PV).
- Calculation of cumulative annual breast cancer incidence at 2, 5, and 10+ years post-ovarian cancer diagnosis.
- Analysis of breast cancer pathology and mortality in relation to prior ovarian cancer diagnosis.
Main Results
- Breast cancer incidence was low at 2 years (1.18%) and 2-5 years (1.13%) but rose significantly after 10 years (>4% annually) for BRCA1 PV carriers.
- BRCA1 PV carriers diagnosed with breast cancer post-ovarian cancer showed less high-grade triple-negative and more lower-grade hormone-receptor-positive disease.
- Breast cancer accounted for <4% of all deaths in the cohort but was the cause of death in 50% of women who developed breast cancer after ovarian cancer.
Conclusions
- Breast cancer incidence is initially low after ovarian cancer diagnosis in BRCA1/BRCA2 PV carriers, potentially due to platinum-based chemotherapy.
- Awareness of increasing breast cancer incidence over time, particularly beyond 10 years, is crucial for these women.
- While initial risk is reassuring, long-term surveillance for breast cancer is warranted.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...